CONCORDBIO vs PGHL: Stock Comparison
Concord Biotech Limited vs Procter & Gamble Health Limited
Live data: 22 July 2026, 3:03 PM IST • Source: NSE and company filings
Concord Biotech Limited is the larger company by market capitalisation. Concord Biotech Limited shows lower leverage and a higher net margin, while Procter & Gamble Health Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Concord Biotech Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CONCORDBIO | PGHL |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | CONCORDBIO | PGHL |
|---|---|---|
| Live Price | ₹1,285.8 | ₹6,737 |
| Day Change | -3.27% | -0.63% |
| Volume | 76,685 | 4,611 |
| 52-Week High | ₹1,980 | ₹6,975 |
| 52-Week Low | ₹987 | ₹4,707 |
| Distance from 52W High | -35.06% | -3.41% |
Valuation
| Metric | CONCORDBIO | PGHL |
|---|---|---|
| Market Cap | ₹13,398 Cr | ₹11,172 Cr |
| P/E Ratio | 53.3x | 34.28x |
| P/B Ratio | 6.89x | 21.36x |
| EPS | ₹24.83 | ₹196.64 |
| Book Value | ₹192.81 | ₹316.01 |
| Dividend Yield | 0.57% | 2.34% |
Growth
| Metric | CONCORDBIO | PGHL |
|---|---|---|
| Revenue Growth (TTM YoY) | -24.1% | 19.1% |
| EPS Growth (TTM YoY) | -37% | 54.6% |
| Qtr Sales Growth | -24.2% | 19.1% |
| Qtr Profit Growth | -36.8% | 54.6% |
Profitability & Leverage
| Metric | CONCORDBIO | PGHL |
|---|---|---|
| ROE | 13.8% | 61.6% |
| ROCE | 18.2% | 83.5% |
| Net Margin | 24.6% | 23.22% |
| Operating Margin | 34.8% | 32.4% |
| Debt to Equity | 0x | 0.02x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | CONCORDBIO | PGHL |
|---|---|---|
| Promoter Holding | 44.08% | 0% |
| FII Holding | 7.8%▲ 0.22 pp | 6.33%▲ 0.13 pp |
| DII Holding | 9.22%▼ 0.36 pp | 12.44%▼ 1.23 pp |
| Public Holding | 38.9%▲ 0.14 pp | 29.42%▲ 1.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Concord Biotech Limited and Procter & Gamble Health Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.